The company announced that as it moves toward the goal of federal approval of RespRX, its website will be updated regularly with information about the applications’ status, as well as ongoing RespRX investigations and developments, KALY stated in a press release.
Increasing evidence suggests that non-psychotropic cannabis-derived compounds, such as pharmaceutical grade cannabidiol (CBD), may hold clinically relevant effects that can help those affected by a wide range of illnesses.
RespRX, also known as NCMB1, is a new CBD formulation that has been developed from KALY’s proprietary botanical extraction process.
“The CBD formulation for the treatment of symptoms associated with COPD and other respiratory conditions is clearly unique, and the testing to date has demonstrated sufficient efficacy to warrant our patent protection,” said Fredrick Ferri, CEO of KALY.
Preliminary results from a study conducted with primates exhibiting symptoms associated with COPD revealed that treatment with RespRX could induce significant increases in respiration rate and inspiratory air flow rate within just two weeks. “These data demonstrate that (…) [RespRX] may have important clinical uses in patients with lung diseases that restrict inspiratory air flow with minimal adverse side effects,” according to the company’s new website.
KALY announced in January that it had concluded preclinical genomics studies in which it successfully tested the impact of its pharmaceutical-grade cannabis extracts in combination with other therapies on COPD patients. Those results supported further studies, for which results are expected to be released by the end of this year.
While there’s no cure for COPD, lifestyle changes, including quitting smoking and avoiding places with dust, fumes or chemicals, can help relieve symptoms and slow disease progression. Treatments include bronchodilators, steroids, and lung therapy. Surgery may be recommended for those with severe forms of COPD.
The company uses its proprietary cannabinoid product platform to discover, develop and commercialize new therapeutics in conditions that also include epilepsy, type 2 diabetes, and cancer pain management.